ArticleJournal of immunology research2014

Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Su-xia Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.